12/27
08:11 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock.
Medium
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock.
12/27
05:44 am
kymr
Rating for KYMR
Medium
Report
Rating for KYMR
12/10
12:53 pm
kymr
Rating for KYMR
Low
Report
Rating for KYMR
12/10
08:58 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BTIG Research. They set a "buy" rating and a $60.00 price target on the stock.
Medium
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BTIG Research. They set a "buy" rating and a $60.00 price target on the stock.
12/10
07:16 am
kymr
Kymera Therapeutics initiated with a Buy at BTIG
Low
Report
Kymera Therapeutics initiated with a Buy at BTIG
12/6
08:06 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating and a $55.00 price target on the stock.
Medium
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating and a $55.00 price target on the stock.
12/6
06:05 am
kymr
Rating for KYMR
Medium
Report
Rating for KYMR
12/6
06:05 am
kymr
Rating for KYMR
Medium
Report
Rating for KYMR
12/5
04:11 pm
kymr
Kymera Therapeutics initiated with a Market Perform at BMO Capital
Medium
Report
Kymera Therapeutics initiated with a Market Perform at BMO Capital
12/5
04:11 pm
kymr
Kymera Therapeutics initiated with a Market Perform at BMO Capital
Medium
Report
Kymera Therapeutics initiated with a Market Perform at BMO Capital
12/2
08:06 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $57.00 price target on the stock, up previously from $38.00.
Low
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $57.00 price target on the stock, up previously from $38.00.
12/2
06:27 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
12/2
06:27 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
11/18
10:14 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
11/18
08:50 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
High
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
11/18
08:50 am
kymr
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
High
Report
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
11/6
07:27 am
kymr
Rating for KYMR
Medium
Report
Rating for KYMR
11/6
07:27 am
kymr
Rating for KYMR
Medium
Report
Rating for KYMR
11/4
10:58 am
kymr
Rating for KYMR
Low
Report
Rating for KYMR
11/1
03:31 pm
kymr
Rating for KYMR
Low
Report
Rating for KYMR
11/1
03:31 pm
kymr
Rating for KYMR
Low
Report
Rating for KYMR